HER2-positive breast cancers typically have a poor prognosis. The objective of our study was to compare the prognosis of patients with HER2-positive breast cancer diagnosed during pregnancy (HER2-positive BCP) to young women diagnosed with HER2-positive breast cancer outside of pregnancy (HER2 non...
[1] von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012 May ...
[11]Kurozumi S, Padilla M, Kurosumi M, et al. HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients. Breast Cancer Res Treat. 2016;158(1):99-111. [12]van Mackelenbergh MT, Loibl S, Untch ...
[9]Agostinetto, E. et al. HER2-low breast cancer: Molecular characteristics and prognosis. Cancers 13, 2824 (2021). [10]Won, H. S. et al. Clinical significance of HER2-low expression in early breast cancer: A nationwide study from the Korean breast cancer society. Breast Cancer Res. 2...
近期《CLINICAL CANCER RESEARCH》上发表了一篇题目为《What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?》的文章,旨在讨论HER2+/ER+患者与HER2+/ER-患者之间的生物学和临床差异,即短期和长期(确诊后>5年)的预后,对新辅助治疗的患者...
Loibl S, Untch M, Buyse M, et al. Pathologic complete response (pCR) and prognosis following neoadjuvant chemotherapy plus anti-HER2 therapy of HER2-positive early breast cancer (EBC).Cancer Res. 2020;80(4_Supplement):P5-06-02....
参考文献:Brand~ao et al. What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?[J]. Clin Cancer Res, 2020, Feb 11(online) 仅供医疗卫生专业人士参考 审批编号:CN-52858
[8] Frenel J-S, Lusque A, Mailliez A, Bachelot T, Uwer L, Mouret-Reynier MA, et al. HER2-low metastatic breast cancer (MBC): management and prognosis of a new breast cancer entity in a real-world setting. Ann Oncol. 2021;32(5):S491. ...
[6]Gravalos C,Jimeno A.HER2 in gastric cancer:a new prognostic factor and a novel therapeutic target.Annals of Oncology.Sep 2008;19(9):1523-1529 [7]Shen GS,Zhao JD,Zhao JH,et al.Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection:A large-scale mu...
HER2 is an established therapeutic target in a large subset of women with breast cancer; a variety of agents including trastuzumab, pertuzumab, lapatinib, neratinib and trastuzumab emtansine (T-DM1) have been approved for the treatment of HER2-positive breast cancer. HER2 is also overexpressed in ...